Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma

NCT03899636 is registered in ClinicalTrials.gov with Angiodynamics, Inc. as lead sponsor.

NCT NCT03899636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03899636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
Lead sponsor
Angiodynamics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 23, 2021
Completion date
April 30, 2025
Enrollment
528 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii pancreatic cancer